Why we invested in Atropos Health, a pioneer in evidence-based healthcare
When patients arrive at the hospital, the hope is to leave with an evidence-based, systematic solution to their problem. Although doctors aim to provide these solutions, the process can be inconsistent. Currently, only 14% of daily medical decisions are made based on high-quality evidence. Clinical trials shape most care guidelines and payer decisions, yet they exclude ~70% of the U.S. population, often because potential subjects are excluded from trials due to comorbidities, age, or other considerations. The unfortunate reality of this is that clinicians are forced to rely on prior experience or secondary sources to make decisions, resulting in assumptions, referrals, and time-consuming studies. In other words, the data to insight pipeline in healthcare is clearly broken, and Atropos Health has set out to fix it.
We invested in Atropos Health, a spinout from Stanford Medicine, because of their commitment to transforming healthcare by providing personalized, real-world evidence to inform clinical treatment decisions and research inquiries.
Leveraging hundreds of millions of de-identified records, Atropos Health generates publication-grade real-world evidence reports, called Prognostograms, at unprecedented speeds. These reports are a game-changer for clinicians, researchers, and pharmaceutical companies, enabling them to ask hyper-specific medical questions and receive clinical-grade reports and analysis on specific patient populations within 48 hours or less. In essence, Atropos empowers healthcare professionals to aggregate real-world evidence, making well-informed decisions a reality.
Atropos Health provides a pioneering platform for rapid data analysis, evidence creation, and Generative AI research and care innovation, primarily aimed at addressing complex healthcare challenges faced by health systems and life science companies worldwide. Their federated Atropos Evidence Platform ensures compliance with data retention, security, and privacy regulations like GDPR, enabling global research collaborations to expedite evidence generation and representation.
The team behind Atropos Health immediately captured our attention. Led by co-founder and CEO Dr. Brigham Hyde, the team boasts a diverse blend of clinical, research, investment, and operational expertise. Brigham’s extensive experience in building health tech companies is complemented by the medical and data science backgrounds of co-founders Dr. Saurabh Gombar and Dr. Nigam Shah to create a strong technical and tactical foundation.
At Samsung Next, we recognize the power of aggregating, analyzing, and summarizing real-world clinical data across diverse sources, and realize how impactful this can be to Samsung. As Samsung expands its healthcare capabilities, Atropos Health can offer a template to deliver data and insights effectively. With key collaborators such as AWS, Datavant, Mayo Clinic Platform, and Stanford Health Care, research institutions and health tech giants alike are quickly realizing the potential of a solution like Atropos, and we are excited to follow suit.
Our investment in Atropos Health is a testament to our belief that this trailblazing team has the potential to revolutionize how health decisions are made, while saving both time and costs. Atropos Health is on track to make a profound impact on the healthcare industry, and we’re excited to be a part of their journey and look forward to the positive changes they will bring to healthcare worldwide.
Rameen Rana is an investor at Samsung Next. Samsung Next's investment strategy is limited to its own views and does not reflect the vision or strategy of any other Samsung business unit, including, but not limited to, Samsung Electronics.